x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma"s top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

science life sciences

All Episodes

00:24:55

The unintended consequences of small molecules

BioSpace ·

2024/03/14

Continuing on from our previous episode "The gap is where the pain is", this episode focuses on a healthy discussion regarding the IRA, particularly the unintended consequences to small molecule development within the industry and for patients. Topics explored in this discussion are potential reasons behind the small molecule negotiation timeline decision, the antibody drug conjugates (ADC) boom, the investment environment, and positive steps the government is making through legislation

en

00:15:37

The skinny on weight loss, donanemab and the State of...

BioSpace ·

2024/03/13

The weight loss market is the gift that keeps on giving—at least for Novo Nordisk—as Wegovy continues to demonstrate its prowess with label expansion. Also discussed: biosimilar approvals for Fresenius Kabi, and Sandoz. More news at the forefront of Alzheimer's treatment: Eli Lilly's donanemab decision date got pushed and now the FDA wants to discuss the drug’s safety and efficacy at an upcoming adcomm. And finally, politics: President Biden's State of the Union address ruffles

en

00:11:06

The ABCs of ADCs: Why antibody-drug conjugates are so...

BioSpace ·

2024/03/06

These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer's strategic priorities for oncology - focused on ADCs and less on small molecules - and how the market is being influenced by the IRA.

en

00:20:06

The gap is where the pain is: Drug pricing and...

BioSpace ·

2024/02/29

When it comes to drug pricing, there have been (and are) bad actors in the industry, but the conversation usually ends there. Five KOLs from different parts of the industry come together to discuss the complexities surrounding drug spend and pricing, innovation, funding, and the overall healthcare system. This episode explores the drug pricing gap between consumer experience and industry norms. Join Lori and our KOLs as we explore the drivers of healthcare costs, the CBO, rebates, and overall spend

en

00:14:15

Sweet succession: Gonzalez, patent thickets and his...

BioSpace ·

2024/02/28

This week Lori, Greg and Tyler discuss AbbVie: how longtime CEO Richard Gonzalez navigated Humira's LOE, his victorious retirement announcement, and the future of biosimilars.Also discussed: Earlybird Health's $186m VC fund; and definitely not the IRA.

en

00:13:30

Iovance wins with Amtagvi and the ADC train chugs on

BioSpace ·

2024/02/21

This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.

en

00:29:06

Eyes on the prize: Novo buys Catalent

BioSpace ·

2024/02/14

This week, Greg, Heather and Tyler discuss reaction to Novo Nordisk's purchase of Catalent and speculate on what that means for existing manufacturing contracts, customers and consequences with regulators; as well as discussion around the ongoing issues with drug shortages and manufacturing challenges and whether it the move will help accelerate manufacturing for Wegovy and Ozempic. Plus, what's next for Alzheimer's treatment following Biogen's withdrawal of Aduhelm? As mentioned in

en

00:20:36

Balancing act: Patient access and innovation

BioSpace ·

2024/02/07

This week Lori, Greg and Tyler discuss drug pricing reforms. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare price negotiations. What's the best way forward that benefits patients while still supporting the innovation that makes these drugs possible? How will the election impact negotiations? Also discussed earnings including Novo Nordisk, who beat analyst expectations largely due to sales of Ozempic and Wegovy, AbbVie, Merck, and GSK.

en

00:17:40

Keep calm and CAR-T on?

BioSpace ·

2024/01/31

Almost 30,000 patients have now been treated with CAR-T cell therapies since it was the first approval in 2017. In November 2023, the FDA launched a probe into malignancies caused by CAR T therapies, and just last week the agency called for a class-wide box warning on all commercial CAR-T therapies with ongoing investigations into cases of secondary malignancies. How do we approach this balancing act of treatment and side effects? Also this week: IPOs march on with ArriVent, CG Oncology, Alto

en

00:18:18

What can biopharma expect from the job market?

BioSpace ·

2024/01/25

Following a challenging year of layoffs and limited funding, Chantal Dresner, VP of Marketing at BioSpace, discusses the findings of our most recent Employment Outlook Report including unemployment, anticipated job search activity, hiring trends and current workforce sentiment.

en

00:10:44

Grab an umbrella, it's raining ⁠IPOs⁠!

BioSpace ·

2024/01/24

The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements. Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.

en

00:13:55

Optimistic, but for how long? Our big takeaways from...

BioSpace ·

2024/01/17

The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco. There was an air of hope and optimism concerning biopharma funding - but will it last? Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.

en

00:12:26

On the ground at #JPM2024 - Day 3 highlights

BioSpace ·

2024/01/10

We're still in San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day three: disruptive AI ⁠is still a hot topic including generative AI; M&A and VC funding; and general whiffs of cautious optimism. Join Lori, Greg and Tyler as they discuss what's been top of mind today. You can ⁠⁠⁠follow our coverage⁠⁠⁠ as our team adds updates throughout the day.

en

00:12:15

On the ground at #JPM2024 - Day 2 highlights

BioSpace ·

2024/01/10

Once again we're recording from San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day two: AI, cell and gene therapy innovation and pricing, and the risks of CAR T cell therapy. Join Lori, Greg and Tyler as they discuss what's been top of mind. You can ⁠⁠follow our coverage⁠⁠ as our team adds updates throughout the day. Join us tomorrow for Day 3 highlights!

en

00:10:04

On the ground at #JPM2024 - Day 1 highlights

BioSpace ·

2024/01/08

Hello from San Francisco! BioSpace is reporting from #JPM2024 bringing you key takeaways and highlights from day one. Join Lori, Greg and Tyler as they discuss what's moving and shaking. You can ⁠follow our coverage⁠ as our team adds updates throughout the day. Get Greg's take on ⁠what this year might hold⁠ in store and how the Biden administration's policies may ⁠play a role in discussions⁠. Join us tomorrow for Day 2 highlights!

en

00:48:20

Alternative funding strategies to discuss at JPM with...

BioSpace ·

2024/01/04

The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited before taking the plunge. Given the current economic environment that is causing challenges in biopharma, how should companies be approaching funding in 2024? Listen to this discussion on different kinds of funding options available, how companies can optimize their chances to secure funding and how they

en

00:14:51

The top life sciences startups to watch this year

BioSpace ·

2024/01/03

Welcome to 2024! This week we're discussing BioSpace's tenth annual list of the hottest new life sciences companies in the U.S. NextGen Class of 2024⁠ includes organizations that launched between September 2022 and September 2023 with a Series A funding. BioSpace's Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss.

en

00:44:37

What VCs look for when investing with MPM Capital,...

BioSpace ·

2023/12/21

How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice and recommendations on how biopharma startups should approach funding. Host ⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠, Head of Insights, BioSpace Guests ⁠Ansbert Gadicke⁠, Managing Director, MPM Capital ⁠Martin Gershon⁠, Managing Partner & CIO, Endeavor Venture Fund ⁠Mike Goguen⁠, Founder and Managing Partner, Two

en

00:16:07

Every move you make: Biopharma industry under heavy...

BioSpace ·

2023/12/20

Biden administration flexes regulatory muscles, putting pressure on the biopharma industry over ‘price gouging’ and invoking march-in rights; meanwhile Sanofi throws in towel over threat of injunction Renewed interest in psychedelics after MindMed’s Phase IIb trial of its LSD-based candidate meets primary endpoint in patients with generalized anxiety disorder. Bluebird bio changes its tune, signing an ‘outcomes- based’ agreement with commercial payer, and Pfizer struggles continue

en

00:22:18

What VCs really think of the market right now with...

BioSpace ·

2023/12/14

What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding outlook with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen. Host ⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠, Head of Insights, BioSpace Host ⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace Guests ⁠⁠Ansbert Gadicke⁠⁠, Managing Director, MPM Capital ⁠⁠Martin Gershon⁠⁠, Managing Partner & CIO, Endeavor Venture Fund ⁠⁠Mike Goguen⁠⁠, Founder

en

191 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter